Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safe Baby Products Act

This article was originally published in The Tan Sheet

Executive Summary

Sen. Kirsten Gillibrand, D-N.Y., introduces S. 295 to direct FDA to investigate cosmetics and personal care marketed to and used by children, according to April 29 release. The bill also would require FDA "to test a wide range of children's personal-care products, publicly report the findings and establish good manufacturing practices to reduce or eliminate hazardous contaminants from products." The legislation responds to the Campaign for Safe Cosmetics' "Toxic Tub" report, which analyzed and identified children's products containing suspected carcinogens 1,4-dioxane and formaldehyde. At the time of the report's release, Gillibrand said she would explore legislation to have FDA more closely scrutinize baby products (1"The Rose Sheet" March 23, 2009, p. 3). Sens. Dianne Feinstein, D-Calif., and Charles Schumer, D-N.Y., are co-sponsors

You may also be interested in...



More “Toxic Tub” Fallout: Senator Gillibrand Decries “Total Lack Of Oversight”

Sen. Kirsten Gillibrand, D-N.Y., is the latest Democrat to speak out about what she perceives as "a complete and total lack of oversight" in the personal-care sector, based on findings from the Campaign for Safe Cosmetics "Toxic Tub" report

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel